Regenerative medicine

Research Report with COVID-19 Forecasts - Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio

Tuesday, May 26, 2020 - 12:00am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our regenerative medicine market report covers the following areas:
    This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the regenerative medicine market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Friday, May 22, 2020 - 10:15pm

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the COVID-19 Pandemic

Wednesday, May 20, 2020 - 2:00pm

Washington, DC, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today.

Key Points: 
  • Washington, DC, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today.
  • More than 120 ARM members are participating in the event, making this year ARMs largest Fly-In to date.
  • Participants will form 24 state delegations to meet with Members of Congress via video calls and teleconferencing systems.
  • The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.

Regenerative Medicine Industry Outlook to 2025 Featuring Novartis, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Roche and More

Thursday, May 14, 2020 - 2:00pm

Additionally, high prevalence of chronic & genetic dieses, emergence of stem cell technology and growing aging populations are some of the key factors driving the regenerative medicine market.

Key Points: 
  • Additionally, high prevalence of chronic & genetic dieses, emergence of stem cell technology and growing aging populations are some of the key factors driving the regenerative medicine market.
  • Increasing number of cancer patients, neurodegenerative, orthopedic, and other aging-associated disorders is creating a significant demand for the regenerative medicine market globally.
  • The Global Regenerative Medicine Market also faces some restraints like high treatment costs, stringent government regulations and operative inefficiency.
  • Based on material, the regenerative medicine market is segmented into synthetic material, biologically derived material, genetically engineered material and pharmaceutical.

Global Regenerative Medicine Markets, 2015-2025 - Impact of COVID-19, Trends & Developments, Competitive Landscape - ResearchAndMarkets.com

Thursday, May 14, 2020 - 10:35am

Additionally, high prevalence of chronic & genetic dieses, emergence of stem cell technology and growing aging populations are some of the key factors driving the regenerative medicine market.

Key Points: 
  • Additionally, high prevalence of chronic & genetic dieses, emergence of stem cell technology and growing aging populations are some of the key factors driving the regenerative medicine market.
  • Increasing number of cancer patients, neurodegenerative, orthopedic, and other aging-associated disorders is creating a significant demand for the regenerative medicine market globally.
  • The Global Regenerative Medicine Market also faces some restraints like high treatment costs, stringent government regulations and operative inefficiency.
  • Based on material, the regenerative medicine market is segmented into synthetic material, biologically derived material, genetically engineered material and pharmaceutical.

BioStem Technologies Announces Corporate Update on Company Direction

Wednesday, April 29, 2020 - 5:35pm

Pompano Beach, FL, April 29, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced a corporate update on the Companys direction.

Key Points: 
  • Pompano Beach, FL, April 29, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced a corporate update on the Companys direction.
  • The Company announced that it embarked on a new initiative to define its two distinct business pillars, BioStem Technologies and BioStem Life Sciences.
  • This new website aligns with the Companys new direction, wherein BioStem Technologies will develop its product pipeline, utilizing BioStem Life Sciences for research, development and manufacturing.
  • About BioStem Technologies, Inc.(OTC PINK: BSEM):BioStem Technologies, Inc.is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine.

2-Day Online Seminar: FDA's Regulation of Regenerative Medicine (including Stem Cell Treatments & Tissue Engineering) April 30th-May 1st, 2020

Monday, April 20, 2020 - 5:30pm

DUBLIN, April 20, 2020 /PRNewswire/ -- The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 20, 2020 /PRNewswire/ -- The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.
  • This seminar will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going.
  • It will also provide few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress.
  • Learn the fundamentals of stem cells and FDA's regulatory approach for its use in medicine.

Online Seminar: FDA's Regulation of Regenerative Medicine including Stem Cell Treatments & Tissue Engineering (April 30, 2020 - May 1, 2020) - ResearchAndMarkets.com

Friday, April 17, 2020 - 4:30pm

The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.
  • This seminar will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going.
  • It will also provide few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress.
  • Learn the fundamentals of stem cells and FDA's regulatory approach for its use in medicine.

RoosterBio Recognized by MTEC with a Multi-Institution Team "Prototype of the Year" Award to Accelerate Regenerative Medicine

Wednesday, April 15, 2020 - 5:00pm

MTEC's "Prototype of the Year" award spotlights breakthroughs developed by RoosterBio and its collaborators since MTEC's 2016 assigned contract of $7.8M to standardize large-scale manufacturing capabilities for clinical grade hMSCs.

Key Points: 
  • MTEC's "Prototype of the Year" award spotlights breakthroughs developed by RoosterBio and its collaborators since MTEC's 2016 assigned contract of $7.8M to standardize large-scale manufacturing capabilities for clinical grade hMSCs.
  • This team's success will facilitate broad adoption of cell manufacturing technology to empower product developers solving real world health challenges.
  • In response to the RFP titled "Biomanufacturing for Regenerative Medicine," the team executed on its project titled "Commercial Scale-Up of Bone Marrow-Derived Mesenchymal Stem Cells for Regenerative Medicine."
  • Since the MTEC contract ended in 2019, RoosterBio has been leveraging the work performed with bone marrow-derived hMSCs into other areas.

The Alliance for Regenerative Medicine to Host FDA Representatives for Webinar on Clinical Trial Guidance During COVID-19 on April 10, 2020

Thursday, April 2, 2020 - 3:11pm

Washington, DC, April 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today announced it will host a webinar on clinical trial guidance during the ongoing COVID-19 pandemic, with speakers from the U.S. Food and Drug Administrations (FDA) Office of Tissues and Advanced Therapies (OTAT).

Key Points: 
  • Washington, DC, April 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today announced it will host a webinar on clinical trial guidance during the ongoing COVID-19 pandemic, with speakers from the U.S. Food and Drug Administrations (FDA) Office of Tissues and Advanced Therapies (OTAT).
  • This webinar will provide additional information to companies looking to conduct cell and gene therapy clinical trials during the COVID-19 pandemic while maintaining high standards for patient safety, good clinical practice, and data integrity.
  • Following presentations from Purohit-Sheth and Irony, the audience will have the opportunity to participate in a live Q&A.
  • The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.